Dr. Sweis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-702-9268
Summary
- I am a board-certified Oncologist with expertise in cancer immunotherapy, genitourinary cancers, developmental therapeutics, and phase I clinical trials.
Education & Training
University of ChicagoPost-Doctoral Fellowship, 2015 - 2017
University of ChicagoFellowship, Hematology and Medical Oncology, 2013 - 2016
University of MichiganResidency, Internal Medicine, 2010 - 2013
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010
Certifications & Licensure
IL State Medical License 2013 - 2026
MI State Medical License 2023 - 2026
OH State Medical License 2024 - 2026
IN State Medical License 2023 - 2025
WI State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CRF Young Investigator Award Cancer Research Foundation, 2018
- ASCO-CCF Lilly Young Investigator Award ASCO - Conquer Cancer Foundation (CCF), 2017-2018
- AACR-BMS Fellowship in Translational Immuno-oncology American Association for Cancer Research (AACR), 2016-2018
- Join now to see all
Clinical Trials
- Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) Start of enrollment: 2013 Dec 30
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer Start of enrollment: 2017 Nov 03
Publications & Presentations
PubMed
- High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai
Breast Cancer Research and Treatment. 2025-02-01 - Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas.Jason J Luke, Randy F Sweis, J Randolph Hecht, Reva Schneider, Mark N Stein
Clinical Cancer Research. 2025-01-23 - A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, Helen Moon, Scott Edward Delacroix
Clinical Cancer Research. 2025-01-17
Journal Articles
- FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder CancerRandy Sweis, MD, Frontiers in Immunology
- T Cell–Inflamed Versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionJason J. Luke, Randy F. Sweis, Clinical Cancer Research
Press Mentions
New Combination Treatment Brings Hope to Advanced Bladder Cancer PatientsSeptember 30th, 2024- New Combination Treatment Brings Hope to Patients with Advanced Bladder CancerSeptember 19th, 2024
- ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
- Join now to see all
Grant Support
- Career Development AwardNIH2017–2019
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- Member
- American Association of Immunologists - AAIMember
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
